← brief for 2026-09-08 · Slowing decline

Eplerenone vs. spironolactone in heart failure: a propensity score-matched analysis of 77 904 patients from a global federated network.

Article C Peer reviewed Observational

Key takeaways

Two closely related heart failure drugs, eplerenone and spironolactone, were compared in 77,904 people using health records from a global database. The study tracked deaths, hospital stays for heart failure, heart attacks and strokes, and whether kidney disease got worse. Because people were not randomly assigned to a drug, this shows a link, not proof that one drug causes better outcomes than the other. Doctors and patients already using one of these drugs may find it useful, but it does not settle the question on its own.

Who did this work

Abomohsen M · Alkuwaiti MA · Alghzawi HM · Hamed BM · Elkasaby MH · Rifai M · Bakr HM · Idries IY · Zepeda IA · Ramasubbu K

Source

Article · PubMed, CKD progression · 2026 Jul 31
https://pubmed.ncbi.nlm.nih.gov/42710016/